IPOs

Kairos goes public with $6M IPO to fund trials of lead cancer drug
Fierce Biotech
Tue, 09/17/24 - 10:54 am
ESMO
Kairos Therapeutics
IPOs
Three biotechs raise $700M in rare burst of IPO activity
BioPharma Dive
Fri, 09/13/24 - 09:22 am
IPOs
Bicara Therapeutics
Zenas BioPharma
MBX Biosciences
MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3
Fierce Biotech
Mon, 09/9/24 - 07:10 pm
MBX Biosciences
IPOs
Yorvipath
Ascendis
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO
Reuters
Fri, 09/6/24 - 10:55 am
Bicara Therapeutics
IPOs
cancer
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Reuters
Fri, 09/6/24 - 10:54 am
Zenas BioPharma
IPOs
Bristol Myers Squibb
obexelimab
BioAge files for IPO, plans pair of midstage obesity trials
Fierce Biotech
Wed, 09/4/24 - 11:40 am
BioAge Labs
IPOs
Eli Lilly
obesity
clinical trials
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Motley Fool
Thu, 08/29/24 - 11:10 am
IPOs
Artiva
autoimmune diseases
cell therapy
AlloNK
Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond
Fierce Biotech
Tue, 08/27/24 - 11:34 am
DualityBio
China
Hong Kong
IPOs
BioNTech
MBX files for IPO, seeking cash to take challenger to Ascendis' Yorvipath into phase 3
Fierce Biotech
Mon, 08/26/24 - 10:09 am
MBX Biosciences
IPOs
Ascendis Pharma
Yorvipath
Bicara and Zenas file for IPOs to push late-phase prospects toward finish line
Fierce Biotech
Fri, 08/23/24 - 10:57 am
Bicara Therapeutics
Zenas BioPharma
IPOs
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Reuters
Thu, 08/22/24 - 10:01 pm
Zenas BioPharma
IPOs
Bristol Myers Squibb
Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO
Fierce Biotech
Thu, 08/15/24 - 11:48 am
Actuate Therapeutics
IPOs
NASDAQ
Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO
Fierce Biotech
Tue, 08/13/24 - 11:32 am
Boundless Bio
layoffs
clinical trials
IPOs
BBI-355
OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs
Fierce Biotech
Thu, 08/1/24 - 11:39 am
OS Therapies
IPOs
Biopharma Investment Activity Continued to Rise in Q2: J.P. Morgan
BioSpace
Wed, 07/31/24 - 11:21 pm
biopharma
funding
IPOs
M&A
Private biotech M&A surges amid difficult IPO market
BioPharma Dive
Mon, 07/22/24 - 06:44 pm
M&A
IPOs
Actuate halves upcoming IPO to just $22M, scaling back clinical plans for cancer drug
Fierce Biotech
Mon, 07/22/24 - 11:32 am
Acuate Therapeutics
IPOs
oncology
Artiva prices $167M IPO, riding optimism for autoimmune cell therapy
BioPharma Dive
Fri, 07/19/24 - 11:43 am
Artiva
IPOs
autoimmune disease
​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work
BioPharma Dive
Fri, 06/28/24 - 11:37 am
Alumis
IPOs
Alumis eyes IPO of over $300M to fund clinical-stage TYK2 pipeline
Fierce Biotech
Mon, 06/24/24 - 10:55 am
Alumis
IPOs
TYK2 inhibitors
ESK-001

Pages